1. Medicines
  2. Cardio-Metabolic
  3. ENTRESTO® (sacubitril/valsartan)

Prescribing information

 

Entresto® (sacubitril/valsartan)

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).1

 

Make Entresto your first choice for your chronic HFrEF patients.

Icon of heart the words 'works directly on the heart

Icon of a chart and the words 'superior efficacy versus ACEi - enalapril'

Icon of a hospital and the words 'alter the cycle of hospitalisation'

 

ACEi, angiotensin converting enzyme inhibitor; HF, heart failure; QoL, quality of life.

References

  1. Entresto Summary of Product Characteristics, 2020.
  2. Kawai T et al. Pharmacol Res 2017; 125:4–13.
  3. Howell EH, Cameron SJ. Cardiol J 2016; 23:591–598.
  4. Januzzi JL Jr et al. JAMA 2019; 322:1085–1095.
  5. Desai AS et al. JAMA 2019; 322:1077–1084.
  6. McMurray JJV et al. N Engl J Med 2014; 371:993–1004.
  7. Velazquez EJ et al. N Engl J Med 2019; 380:539–548.
  8. Claggett B et al. N Engl J Med 2015; 373:2289–2290.
  9. Lewis EF et al. Circ Heart Fail 2017; 10:e003430.
ENT20-C046(2) October 2020.
Cardio-metabolic
Product
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]